
Nurix Therapeutics, Inc. – NASDAQ:NRIX
Nurix Therapeutics stock price today
Nurix Therapeutics stock price monthly change
Nurix Therapeutics stock price quarterly change
Nurix Therapeutics stock price yearly change
Nurix Therapeutics key metrics
Market Cap | 1.40B |
Enterprise value | 397.11M |
P/E | -2.35 |
EV/Sales | 10.28 |
EV/EBITDA | -2.35 |
Price/Sales | 11.64 |
Price/Book | 1.48 |
PEG ratio | 0.05 |
EPS | -2.92 |
Revenue | 62.30M |
EBITDA | -163.98M |
Income | -165.00M |
Revenue Q/Q | -60.58% |
Revenue Y/Y | 2.24% |
Profit margin | -466.93% |
Oper. margin | -476.01% |
Gross margin | 0% |
EBIT margin | -476.01% |
EBITDA margin | -263.21% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeNurix Therapeutics stock price history
Nurix Therapeutics stock forecast
Nurix Therapeutics financial statements
$32.78
Potential upside: 231.42%
Analysts Price target
Financials & Ratios estimates
Aug 2023 | 18.46M | -36.98M | -200.26% |
---|---|---|---|
Nov 2023 | 15.15M | -41.95M | -276.77% |
Feb 2024 | 16.58M | -41.51M | -250.33% |
May 2024 | 12.09M | -44.54M | -368.39% |
Aug 2023 | 308195000 | 74.37M | 24.13% |
---|---|---|---|
Nov 2023 | 364539000 | 164.04M | 45% |
Feb 2024 | 312674000 | 143.92M | 46.03% |
May 2024 | 511031000 | 140.33M | 27.46% |
Aug 2023 | -41.13M | 22.77M | 1.70M |
---|---|---|---|
Nov 2023 | 21.74M | -14.37M | 4.94M |
Feb 2024 | -41.95M | 35.51M | 1.62M |
May 2024 | -39.70M | -131.07M | 237.75M |
Nurix Therapeutics alternative data
Aug 2023 | 297 |
---|---|
Sep 2023 | 297 |
Oct 2023 | 297 |
Nov 2023 | 297 |
Dec 2023 | 297 |
Jan 2024 | 297 |
Feb 2024 | 297 |
Mar 2024 | 284 |
Apr 2024 | 284 |
May 2024 | 284 |
Jun 2024 | 284 |
Jul 2024 | 284 |
Nurix Therapeutics other data
Period | Buy | Sel |
---|---|---|
Jan 2024 | 0 | 5765 |
Feb 2024 | 0 | 6812 |
Apr 2024 | 0 | 4907 |
May 2024 | 0 | 3499 |
Jun 2024 | 0 | 25760 |
Jul 2024 | 0 | 14578 |
Aug 2024 | 0 | 39107 |
Sep 2024 | 0 | 9050 |
Oct 2024 | 0 | 19037 |
Nov 2024 | 0 | 12596 |
Dec 2024 | 0 | 5760 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | RING CHRISTINE officer: Chief Le.. | Employee Stock Option (right to buy) | 5,760 | $1.86 | $10,714 | ||
Option | RING CHRISTINE officer: Chief Le.. | Common Stock | 5,760 | $1.86 | $10,714 | ||
Sale | RING CHRISTINE officer: Chief Le.. | Common Stock | 5,760 | $21.73 | $125,153 | ||
Option | RING CHRISTINE officer: Chief Le.. | Employee Stock Option (right to buy) | 3,290 | $9.57 | $31,485 | ||
Option | RING CHRISTINE officer: Chief Le.. | Common Stock | 3,290 | $9.57 | $31,485 | ||
Sale | RING CHRISTINE officer: Chief Le.. | Common Stock | 3,290 | $25 | $82,250 | ||
Option | RING CHRISTINE officer: Chief Le.. | Employee Stock Option (right to buy) | 5,760 | $1.86 | $10,714 | ||
Option | RING CHRISTINE officer: Chief Le.. | Common Stock | 5,760 | $1.86 | $10,714 | ||
Sale | RING CHRISTINE officer: Chief Le.. | Common Stock | 5,760 | $24.28 | $139,864 | ||
Sale | VAN HOUTE HANS officer: Chief Financial Officer | Common Stock | 3,546 | $24.28 | $86,083 |
Patent |
---|
Application Filling date: 4 Feb 2020 Issue date: 12 May 2022 |
Application Filling date: 5 May 2021 Issue date: 18 Nov 2021 |
Application Filling date: 3 Dec 2020 Issue date: 1 Jul 2021 |
Application Filling date: 23 Sep 2020 Issue date: 25 Mar 2021 |
Application Filling date: 23 Sep 2020 Issue date: 25 Mar 2021 |
Application Filling date: 26 Jun 2020 Issue date: 25 Feb 2021 |
Application Filling date: 15 May 2020 Issue date: 25 Feb 2021 |
Application 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS Filling date: 9 Apr 2020 Issue date: 15 Oct 2020 |
Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential
Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation
Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case
Nurix Therapeutics: A Unique Approach To BTK Targeting
Nurix: Still Promising, But No New Development Except Gilead Licensing Asset
Nurix: Promising Early Data From This Protein Degrader Company
Nurix: Down, But Not Out
Nurix: Advancing Targeted Protein Modulation Therapies
Aptose: Cancer Trial Catalyst Ahead At EHA21
-
What's the price of Nurix Therapeutics stock today?
One share of Nurix Therapeutics stock can currently be purchased for approximately $9.89.
-
When is Nurix Therapeutics's next earnings date?
Unfortunately, Nurix Therapeutics's (NRIX) next earnings date is currently unknown.
-
Does Nurix Therapeutics pay dividends?
No, Nurix Therapeutics does not pay dividends.
-
How much money does Nurix Therapeutics make?
Nurix Therapeutics has a market capitalization of 1.40B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 99.31% to 76.99M US dollars.
-
What is Nurix Therapeutics's stock symbol?
Nurix Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "NRIX".
-
What is Nurix Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Nurix Therapeutics?
Shares of Nurix Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Nurix Therapeutics's key executives?
Nurix Therapeutics's management team includes the following people:
- Dr. Arthur T. Sands Chief Executive Officer, Pres & Director(age: 63, pay: $852,770)
- Dr. Gwenn M. Hansen Ph.D. Chief Scientific Officer(age: 54, pay: $673,850)
- Dr. Christine Ring Gen. Counsel & Sec.(age: 60, pay: $548,450)
-
How many employees does Nurix Therapeutics have?
As Jul 2024, Nurix Therapeutics employs 284 workers.
-
When Nurix Therapeutics went public?
Nurix Therapeutics, Inc. is publicly traded company for more then 5 years since IPO on 24 Jul 2020.
-
What is Nurix Therapeutics's official website?
The official website for Nurix Therapeutics is nurixtx.com.
-
Where are Nurix Therapeutics's headquarters?
Nurix Therapeutics is headquartered at 1700 Owens Street, San Francisco, CA.
-
How can i contact Nurix Therapeutics?
Nurix Therapeutics's mailing address is 1700 Owens Street, San Francisco, CA and company can be reached via phone at +41 56605320.
-
What is Nurix Therapeutics stock forecast & price target?
Based on 8 Wall Street analysts` predicted price targets for Nurix Therapeutics in the last 12 months, the avarage price target is $32.78. The average price target represents a 231.42% change from the last price of $9.89.
Nurix Therapeutics company profile:

Nurix Therapeutics, Inc.
nurixtx.comNASDAQ
284
Biotechnology
Healthcare
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
San Francisco, CA 94158
CIK: 0001549595
ISIN: US67080M1036
CUSIP: 67080M103